6618:HKEXJD Health International, Inc. Analysis
Data as of 2026-03-14 - not real-time
HK$49.00
Latest Price
4/10Risk
Risk Level: Medium
Executive Summary
JD Health is trading at HK$49, notably below its 20‑day SMA of 54.27 and 50‑day SMA of 59.44, indicating short‑term pressure but also a clear reversion gap. The RSI of 32 points to oversold conditions, while the MACD remains bearish (line under signal), yet volume is increasing and price stays above the computed support of HK$45, providing a cushion. Volatility is high at 42.8% over 30 days, but a low beta of 0.25 limits market‑wide swings.
Fundamentally, JD Health delivers strong 28% revenue growth and a forward PE of 17.66 versus a trailing PE of 25.5 and industry PE of 26.2, suggesting relative cheapness. The DCF‑derived fair value of HK$86.9 implies roughly 55% upside, consistent with a strong‑buy consensus (median target HK$70.84) and a Fear & Greed index of 72.9 (Greed). Robust cash balances, modest debt, and favorable growth trends make JD Health a compelling buy despite short‑term technical headwinds.
Fundamentally, JD Health delivers strong 28% revenue growth and a forward PE of 17.66 versus a trailing PE of 25.5 and industry PE of 26.2, suggesting relative cheapness. The DCF‑derived fair value of HK$86.9 implies roughly 55% upside, consistent with a strong‑buy consensus (median target HK$70.84) and a Fear & Greed index of 72.9 (Greed). Robust cash balances, modest debt, and favorable growth trends make JD Health a compelling buy despite short‑term technical headwinds.
Market Outlook
Short Term
< 1 yearPositive
Model confidence: 7/10
Key Factors
- Oversold RSI indicating near‑term bounce potential
- Price above strong support at HK$45
- Increasing volume supporting upside
Medium Term
1–3 yearsPositive
Model confidence: 8/10
Key Factors
- Substantial valuation upside (~55%) to DCF fair value
- Robust revenue growth and improving forward PE
- Analyst consensus of strong‑buy with median target above current price
Long Term
> 3 yearsPositive
Model confidence: 9/10
Key Factors
- Long‑term digital health tailwinds in China
- Strong cash position and low leverage
- Undervalued relative to fair‑value and industry peers
Key Metrics & Analysis
Financial Health
Revenue Growth28.00%
Profit Margin7.32%
P/E Ratio25.5
ROE9.31%
ROA3.11%
Debt/Equity1.06
P/B Ratio2.3
Op. Cash FlowHK$10.2B
Free Cash FlowHK$6.2B
Industry P/E26.2
Technical Analysis
TrendNeutral
RSI32.0
SupportHK$45.02
ResistanceHK$61.35
MA 20HK$54.27
MA 50HK$59.44
MA 200HK$56.95
MACDBearish
VolumeIncreasing
Fear & Greed Index72.88
Valuation
Fair ValueHK$86.89
Target PriceHK$75.88
Upside/Downside54.86%
GradeUndervalued
TypeBlend
Risk Assessment
Beta0.25
Volatility42.84%
Sector RiskMedium
Reg. RiskMedium
Geo RiskMedium
Currency RiskLow
Liquidity RiskLow
Similar Tickers
This analysis may contain inaccuracies and is provided for informational and research purposes only. It is not personal investment advice, a recommendation, or an instruction to buy, sell, or hold any asset.